Stephen Haworth
Hoofd Techniek/Wetenschap/O&O bij XORTX THERAPEUTICS INC.
Vermogen: - $ op 31-05-2024
Profiel
Stephen Haworth is currently the Chief Medical Officer at XORTX Therapeutics, Inc. He previously worked as the Executive Director-Medical at CorMedix, Inc. from 2017 to 2018, and as the Chief Medical Officer & Vice President at Elusys Therapeutics, Inc. from 2012 to 2013.
He also served as the Vice President at VaxInnate Corp.
from 2015 to 2016.
Haworth received his undergraduate degree from University College London and his doctorate from UCL Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
XORTX THERAPEUTICS, INC.
-.--% | 04-03-2024 | 0 ( -.--% ) | - $ | 31-05-2024 |
Actieve functies van Stephen Haworth
| Bedrijven | Functie | Begin |
|---|---|---|
| XORTX THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2021 |
Eerdere bekende functies van Stephen Haworth
| Bedrijven | Functie | Einde |
|---|---|---|
| CORMEDIX INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Hoofd Techniek/Wetenschap/O&O | 01-04-2013 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | 01-04-2016 |
Opleiding van Stephen Haworth
| UCL Medical School | Doctorate Degree |
| University College London | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| XORTX THERAPEUTICS INC. | Health Technology |
| CORMEDIX INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
